Another milestone to making it a cornerstone. MindBio Therapeutics

Incredible news from MindBio Therapeutics finance.yahoo.com/news/mindbio-t…

Enveric Biosciences, Inc.'s news announcing the signing of three non-binding term sheets to pursue the exclusive out-licensing of three classes of compounds with an undisclosed biotechnology company is featured in a Benzinga exclusive article. Read the article here: benzinga.com/general/biotec…

We backed CybinInc at day zero. Incredible moment and hope for the future. ir.cybin.com/investors/news…

Bravo to our portfolio company Gilgamesh Pharma prnewswire.com/news-releases/…

Excellent data for atai Life Sciences's & their subsidiary Beckley Psytech's Phase 2a open label study of BPL-003 (intranasal 5-MeO-DMT) in patients who suffer from treatment-resistant depression (TRD). In summary, the Phase 2a results of BPL-003 demonstrated: 1) Rapid-acting

Our portfolio company HIVE BIO features in The Times and The Sunday Times look at #Malta & #Gozo emerging wellness market. thetimes.co.uk/article/why-ma…

Happy Bicycle Day - every day we edge closer. 🚴🏻🍄. To every entrepreneur trying to change the world. It’s a marathon not a sprint. Honoured to be working with so many of you.

ANNOUNCEMENT: We have partnered with @AbbVie through a collaboration and option-to-license agreement to advance the development of groundbreaking therapies for psychiatric disorders. Learn more prnewswire.com/news-releases/…

This morning's news: Enveric Biosciences, Inc. Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders enveric.com/news/enveric-b…

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement - Aries to clinically develop and market Enveric’s patented product for radiation dermatitis Aries Science & Technology, LLC & Enveric Biosciences, Inc. enveric.com/news/aries-sci…

Our team has made excellent progress this quarter on our #clinical programs. ✔️Announced Phase 1b results for VLS-01 (oral buccal film DMT), with a Phase 2 study in 142 patients with treatment-resistant #depression expected to initiate around year end. See our new corporate

"This is the biggest breakthrough in psychiatry in 40 years." Yesterday, Doug Drysdale made a guest appearance on Dr. Drew on FOX Business to talk about the breakthrough innovations Cybin is developing to revolutionize the treatment of mental health. Watch:

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - businesswire.com/news/home/2024…

We are #hiring! ASSOCIATE DIRECTOR, CLINICAL DEVELOPMENT – ADDITIONAL HIRE United States, Remote, Full-time linkedin.com/jobs/view/4136… Do you know a potential future Cybinaut? Send them the link to apply!

Enveric Biosciences, Inc. recent news was featured in Microdose Psychedelic Insights Link to article: microdose.buzz/news/enveric-b… $ENVB #MentalHealth #NeuroScience #Biotech

“It is gratifying that the U.S. FDA Commissioner Dr. Martin Makary shares our belief in the potential therapeutic value of these innovative treatments – a long-held belief that stands at the core of Cybin’s mission,” said Doug Drysdale, Chief Executive Officer of Cybin. Watch Dr.

Enveric Biosciences, Inc. Identifies #Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease - Files provisional patent application on newly identified group of molecules #NeurodegenerativeDisease - #psychedelics #mentalhealth enveric.com/news/enveric-b…

Thanks Microdose Psychedelic Insights for covering our news this morning - Enveric Biosciences Stakes Its Claim in Neurodegeneration Market $ENVB #Neurodegeneration #neuroplasticity microdose.buzz/news/enveric-n…

Today we announced positive topline data from our Phase 2a study of GM-2505 for Major Depressive Disorder. Read more: prnewswire.com/news-releases/…